Highbridge Capital Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Highbridge Capital Management’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-87,200	Closed	-$460K	–	1832
2016 Q1	$460K	Buy	87,200 +71,800	+466%	+$439K	0.01%	1013
2015 Q4	$121K	Sell	15,400 -199,900	-93%	-$1.72M	﹤0.01%	1409
2015 Q3	$1.82M	Buy	+215,300	New	+$1.99M	0.03%	572
2014 Q4	–	Sell	-58,000	Closed	-$779K	–	1494
2014 Q3	$779K	Buy	+58,000	New	+$691K	0.01%	742

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Highbridge Capital Management's INFI Position: Q2 2017 in Review

Highbridge Capital Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2017, closing a stake of 32,793 shares — an estimated $106K sold.

Highbridge Capital Management first reported a position in INFI in Q2 2013 and held it in 6 quarters. The position peaked at $2.06M in Q2 2013. 74 funds tracked by Wall St. Rank hold INFI as of Q2 2017.

Highbridge Capital Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 32,793 Infinity Pharmaceuticals, Inc. shares in Q2 2017, an estimated $106K.
Highbridge Capital Management first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 6 quarters.
Highbridge Capital Management's Infinity Pharmaceuticals, Inc. position peaked at $2.06M in Q2 2013.
74 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.